Researchers led by Nagoya University unveiled a next-generation CAR-T cell therapy designed to target solid tumors by recognizing the antigen Eva1 (MPZL2), expressed prevalently in lung, pancreatic, and liver cancers. The engineered CAR-T cells feature optimized spacer and intracellular domains to enhance immunological synapse formation and cytotoxic potency. This innovation aims to surmount traditional barriers in solid tumor immunotherapy by improving T-cell activation and antitumor efficacy, marking a significant leap in cancer treatment strategies.